



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/073,863	02/14/2002	Gholam A. Peyman	42561	6337

7590 03/21/2005  
Roylance, Abrams, Berdo & Goodman, L.L.P.  
Suite 600  
1300 19th Street, N.W.  
Washington, DC 20036

EXAMINER

SHEIKH, HUMERA N

ART UNIT PAPER NUMBER

1615

DATE MAILED: 03/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 10/073,863	<b>Applicant(s)</b> PEYMAN, GHOLAM A.	
	<b>Examiner</b> Humera N. Sheikh	<b>Art Unit</b> 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 26 November 2004.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,4-10,13-32 and 34-40 is/are pending in the application.  
     4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 28-31 is/are allowed.
- 6) ☒ Claim(s) 1, 4-10, 13-27, 32 and 34-40 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
     a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |                                                                                                                        |                                                                                         |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                                                       | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____                                                |

## **DETAILED ACTION**

### **Status of the Application**

Receipt of the Amendment and Applicant's Arguments/Remarks, both filed 11/26/04 is acknowledged.

Claims 1, 4-10, 13-32 and 34-40 are pending. Claims 1, 10, 20, 23 and 28 have been amended. Claims 1, 4-10, 13-27, 32 and 34-40 remain rejected. Claim 28 is objected to. Claims 28-31 are allowable upon overcoming the claim 28 objection.

### ***Claim Objections***

Claim 28 is objected to because of the following informalities:

The term '*animal*' is absent from the limitation in claim 28, line 3. Appropriate correction is required.

### ***Claim Rejections - 35 USC § 103***

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The scope of the claims is being examined in terms of the presence of two fluorescent dyes that excite at different temperatures in the presence of a bioactive agent.

**Claims 1, 4-10, 13-27, 32 and 34-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zeimer (US Pat. No. 5,935,942) in view of Khoobehi *et al.* (US Pat. No. 5,976,502) and further in view of Rahman *et al.* (US Pat. No. 3,993,754).**

Zeimer teaches methods and materials for chemically treating a target site by utilizing fluorescent dyes and tissue-reactive substances that are encapsulated within heat-sensitive liposomes, wherein the liposomes release their contents of fluorescent dyes at a temperature of approximately 41°C (see reference column 3, line 10 through col. 7, line 64); and abstract.

According to Zeimer, the method involves co-administering intravenously a fluorescent dye encapsulated within heat-sensitive liposomes and a tissue-reactive agent which is effective to cause chemical tissue damage following its activation; non-invasively heating tissue at a pre-determined anatomical locus within the eye so that the heat-sensitive liposomes leak and release their contents into the blood vessel or sinus at the predetermined locus; exciting the fluorescent dye; visually observing a pattern of fluorescent vasculature which develops at the pre-determined locus; and activating the tissue-reactive agent disposed within the blood vessel or sinus so that the blood vessel or sinus is chemically damaged to an extent sufficient to occlude the vessel or sinus (col. 3, lines 10-24).

Zeimer teaches that the blood vessel or sinus is selectively and non-invasively heated to a temperature of approximately 41°C by irradiating with a laser beam having a wavelength absorbed by blood (col. 7, lines 53-57).

The heat-sensitive liposomes include physiologically compatible constituents, such as dipalmitoylphosphatidylcholine and dipalmitoylphosphatidyl-glycerol phospholipids, that permit

Art Unit: 1615

preparation of liposomes using art-recognized techniques that release their contents at temperatures above those of the mammalian body temperature, i.e., above 37°C. Upon exposure to temperatures at least about 40°C, above mammalian temperature, release occurs by leakage or seepage of the liposomes contents or by lysis of the liposomes (col. 7, lines 10-20).

Additionally, the laser-targeted occlusion method also comprises co-administration of an anti-inflammatory agent or an antibiotic encapsulated within the heat-sensitive liposomes. Antibiotics include anti-bacterial, anti-fungal, anti-neoplastic and anti-parasitic antibiotics. Anti-neoplastic antibiotics include aclacinomycins, bleomycins, chromomycins, mitomycins and the olivomycins (col. 12, lines 51-59).

Zeimer is deficient only in the sense that he does not explicitly teach a first and second encapsulated fluorescent dye.

**Khoobehi *et al.*** teach a method of observing blood flow through the eye by injecting a carrier, such as liposomes and blood cells containing the dye, into the blood stream whereby the carrier can contain a single dye or a mixture of different dyes. The mixture can be of a first carrier containing a dye capable of fluorescing when exposed to a laser beam in the visible range and a second carrier containing a dye capable of fluorescing when exposed to a red or infrared laser beam. In addition, the cells can be stained with two different lipophilic dyes where the first dye fluoresces when exposed to a red or infrared laser beam and a second dye fluoresces when exposed to a laser beam in the blue-green spectral range (see reference column 3, line 25 through col. 5, line 5).

It would have been obvious to one of ordinary skill in the art to use either a single fluorescent dye or a mixture of different fluorescent dyes as taught by Khoobehi et al. within the methods taught by Zeimer, because Khoobehi et al. explicitly teach liposomes containing a mixture of dyes which serve to enable the dyes to fluoresce when exposed to various types of lasers (i.e., visible range or infrared-spectral range) and similarly Zeimer teaches a method of chemically treating a target site by utilizing fluorescent dyes in order to visualize patterns of fluorescence. The expected result would be a highly effective method of targeting specific tissue sites and observing carriers, particularly liposomes.

Zeimer does not teach hyperthermally treating tissue for a time sufficient to kill cells.

**Rahman et al.** teach a liposome-encapsulated anti-tumor drug, actinomycin, for cancer chemotherapy wherein the encapsulated drug, actinomycin penetrates into tumor cells where it is slowly released to induce degeneration and death of tumor cells. According to Rahman et al., the liposome-encapsulation of actinomycin is effective in causing degeneration and death of tumor cells, while reducing any toxicity to the host body (see reference column 2, lines 5-38) and Abstract.

It would have been obvious to one of ordinary skill in the art to use the combined teachings of Rahman et al. within Zeimer, because Rahman et al. teach liposome-encapsulated anti-tumor drugs, such as actinomycin, which is a known antineoplastic agent used to effectively combat tumor cells and similarly, Zeimer teaches treating target sites by utilizing fluorescent dyes and tissue-reactive substances that are encapsulated within heat-sensitive liposomes, to

cause chemical tissue damage. The expected result would be an improved method of employing liposome-encapsulated drugs containing fluorescent dyes to effectively destroy cells, while simultaneously reducing the level of toxicity to the host.

In summary, the primary reference (Zeimer) teaches the use of fluorescent dyes and tissue-reactive substances that are encapsulated within heat-sensitive liposomes, whereby the dyes are heated to release their contents at a pre-determined anatomical locus. The secondary reference (Khoobehi *et al.*) teaches that it is known to use a mixture of fluorescent dyes using various types of lasers. The tertiary reference (Rahman *et al.*) teaches liposome-encapsulated anti-cancer drugs (i.e., actinomycin) to degenerate and kill cells. It is the position of the Examiner that there is no criticality observed in the instantly claimed temperature of about 45° to about 60° since the claims merely require that the tissues be heated for a sufficient time to kill cells. The tertiary reference of Rahman *et al.* is cited to show that it is well-known to use liposome-encapsulated drugs as a means of chemotherapy for the degeneration and killing of tumor cells. It is *prima facie* obvious to use liposome-encapsulated drugs as a means of treatment in combination with the formulations of the primary references, which provide temperature-indicating means. No criticality is seen in the instantly claimed temperature of about 45° to about 60° since the prior art explicitly teaches effective methods for killing (cancerous) cells.

***Response to Arguments***

Applicant's arguments filed 11/26/04 have been fully considered but they are not persuasive.

Firstly, Applicant argued, "The cited art either taken alone or in combination do not disclose or suggest the claimed steps of heating to thermally treat tissue as in claims 1 and 23 or detecting a threshold temperature as in claim 10. The art does not suggest heating the tissue to the claimed temperatures of at least 47°C. The art avoids extensive cell and tissue damage by heating, and discloses heating only to about 41°C. The passage cited in Zeimer only recognizes that tissue damage can occur by heat, but provides no suggestion that the Zeimer process intends to or in fact causes tissue damage by heating. Zeimer provides no motivation or incentive to heat the tissue to 47°C. The claimed temperature of 50°C is not suggested by Zeimer either alone or in combination with the secondary references."

Applicant's arguments have been fully considered, but were not found persuasive. Zeimer teaches utilizing fluorescent dyes and tissue-reactive substances that are encapsulated within heat-sensitive liposomes, whereby the dyes are heated to release their contents at a pre-determined location. Admittedly, Zeimer teaches heating to only about 41°C, however, the prior art does recognize using liposome-encapsulated materials, such as fluorescent dyes, using a temperature-indicating means and method to effectively chemically treat tissues. The argument that 'the art of record clearly avoids cell/tissue damage' is not persuasive since Zeimer teaches heating tissue to about 41°C, without causing substantial physiological damage (col. 10, lines 9-13), thus indicating that some tissue damage does occur. The claims merely require that the tissues be heated for a sufficient time to kill cells. The reference of Rahman *et al.* is relied upon



for their teaching of using liposome-encapsulated anti-tumor drugs as a means of chemotherapy for the degeneration and killing of tumor cells.

Secondly, Applicant argued, “Khoobehi is cited for disclosing the use of two different liposomes containing different dyes. However, Khoobehi discloses the dyes for use in visualizing the dye in different vessels in the eye to distinguish the blood flow in the different parts of the eye. The lasers do not hyperthermally treat the cells. The method of Khoobehi does not detect or monitor the temperature of the tissue and the method does not use the dyes to indicate that a temperature has been attained.”

Applicant’s arguments were not persuasive. It is of no moment that the secondary reference of Khoobehi utilizes dyes in different vessels of the eye, merely that Khoobehi teach the use of more than one dye that are able to fluoresce when exposed to various types of lasers is sufficient. Khoobehi teach that it is well known in the art to employ either one dye or a mixture of dyes to, in this case, observe blood flow in the eye. Moreover, the argument that the ‘lasers do not hyperthermally treat the cells’ is not persuasive since Khoobehi was relied upon merely to demonstrate the utilization of more than one dye to fluoresce using various laser types and was not relied upon to show the hyperthermal treatment of cells. The argument that “The method of Khoobehi does not detect or monitor the temperature of the tissue and the method does not use the dyes to indicate that a temperature has been attained” is not persuasive since the limitation ‘to indicate that a temperature has been attained’ is a future-intended use limitation, which affords no patentable weight to the claims.

Lastly, Applicant argued “The cited art fails to disclose heating to temperatures as claimed in claim 10. The art does not suggest the bioactive compounds of claims 14-17 in

Art Unit: 1615

combination with the method steps of claim 10. For claim 20, the patents do not suggest reducing the temperature in response to the detection of the dye when the dye fluoresce. Regarding claim 23, the cited art does not suggest heating to release only one of the dyes. The features of claims depending from claim 23 are also not suggested in the art.”

Applicant’s arguments have been carefully considered, but were not found persuasive. While the prior art does not explicitly teach Applicant’s claimed temperatures, the prior art does teach the generic concept of the use of temperature-indicating means to effectively chemically treat tissues. The prior art also teaches using liposome-encapsulated anti-tumor drugs as a means of chemotherapy for the degeneration and killing of tumor cells. Thus, the specific temperatures claimed by Applicant do not patentably distinguish over the teachings of the cited art of record. In view of the teachings of the prior art of record, the instant invention is rendered *prima facie* obvious.

#### ***Allowable Subject Matter***

Claims 28-31 are allowed.

(Note: Correction is required for objected Claim 28.)

#### **Correspondence**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera N. Sheikh whose telephone number is (571) 272-0604.

Art Unit: 1615

The examiner can normally be reached on Monday through Friday from 8:00A.M. to 5:30P.M., alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

H. N. Sheikh



Patent Examiner

Art Unit 1615

March 15, 2005



THURMAN K. PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600